AIMS/HYPOTHESIS: The aims of this study were (1) to determine the prevalence and rate of progression in diabetes secondary to mitochondrial DNA (mtDNA) mutations; and (2) to determine whether percentage heteroplasmy predicts clinical outcome in patients carrying the m.3243A>G mutation. METHODS: We prospectively assessed 242 patients attending a specialist neuromuscular clinic using a validated mitochondrial disease rating scale. Retrospective clinical data on these patients from up to 25 years of follow-up were also included. Percentage heteroplasmy in blood, urine and muscle was determined for the m.3243A>G group and correlated against clinical features. RESULTS: Patients carrying the m.3243A>G mutation formed the largest group of patients with diabetes (31/81 patients). The highest prevalence of diabetes was in the m.12258C>A group (2/2 patients), the lowest in the multiple mtDNA deletions group (3/43 patients). The earliest age of onset was in the m.3243A>G group (37.9 years) with the highest age of presentation in the multiple deletion group (56.3 years). Of patients presenting with m.3243A>G, 12.9% required insulin; an additional 32.3% progressed to insulin requirement over a mean of 4.2 years after presentation. Percentage heteroplasmy in blood, urine or muscle did not predict progression of diabetes or risk of developing complications. Early age of presentation with diabetes did predict poor clinical outcome. CONCLUSIONS/ INTERPRETATION: Although patients carrying the m.3243A>G mutation account for the majority of cases of diabetes secondary to mtDNA mutations, several other genotypes are also associated with the development of diabetes, some with high penetrance. All show a gradual progression to insulin requirement. Percentage heteroplasmy is a poor predictor of severity of diabetes in the m.3243A>G group.
AIMS/HYPOTHESIS: The aims of this study were (1) to determine the prevalence and rate of progression in diabetes secondary to mitochondrial DNA (mtDNA) mutations; and (2) to determine whether percentage heteroplasmy predicts clinical outcome in patients carrying the m.3243A>G mutation. METHODS: We prospectively assessed 242 patients attending a specialist neuromuscular clinic using a validated mitochondrial disease rating scale. Retrospective clinical data on these patients from up to 25 years of follow-up were also included. Percentage heteroplasmy in blood, urine and muscle was determined for the m.3243A>G group and correlated against clinical features. RESULTS: Patients carrying the m.3243A>G mutation formed the largest group of patients with diabetes (31/81 patients). The highest prevalence of diabetes was in the m.12258C>A group (2/2 patients), the lowest in the multiple mtDNA deletions group (3/43 patients). The earliest age of onset was in the m.3243A>G group (37.9 years) with the highest age of presentation in the multiple deletion group (56.3 years). Of patients presenting with m.3243A>G, 12.9% required insulin; an additional 32.3% progressed to insulin requirement over a mean of 4.2 years after presentation. Percentage heteroplasmy in blood, urine or muscle did not predict progression of diabetes or risk of developing complications. Early age of presentation with diabetes did predict poor clinical outcome. CONCLUSIONS/ INTERPRETATION: Although patients carrying the m.3243A>G mutation account for the majority of cases of diabetes secondary to mtDNA mutations, several other genotypes are also associated with the development of diabetes, some with high penetrance. All show a gradual progression to insulin requirement. Percentage heteroplasmy is a poor predictor of severity of diabetes in the m.3243A>G group.
Authors: P F Chinnery; P J Zwijnenburg; M Walker; N Howell; R W Taylor; R N Lightowlers; L Bindoff; D M Turnbull Journal: Am J Med Genet Date: 1999-08-27
Authors: Robert W Taylor; Andrew M Schaefer; Martin J Barron; Robert McFarland; Douglass M Turnbull Journal: Neuromuscul Disord Date: 2004-04 Impact factor: 4.296
Authors: Amanda I Adler; Richard J Stevens; Sue E Manley; Rudy W Bilous; Carole A Cull; Rury R Holman Journal: Kidney Int Date: 2003-01 Impact factor: 10.612
Authors: S Kiechl; R Horváth; P Luoma; U Kiechl-Kohlendorfer; B Wallacher-Scholz; R Stucka; C Thaler; J Wanschitz; A Suomalainen; M Jaksch; J Willeit Journal: J Neurol Neurosurg Psychiatry Date: 2004-08 Impact factor: 10.154
Authors: J Antonie Maassen; Leen M 'T Hart; Einar Van Essen; Rob J Heine; Giel Nijpels; Roshan S Jahangir Tafrechi; Anton K Raap; George M C Janssen; Herman H P J Lemkes Journal: Diabetes Date: 2004-02 Impact factor: 9.461
Authors: Christina Reinauer; Thomas Meissner; Michael Roden; Angelika Thon; Paul-Martin Holterhus; Holger Haberland; Elisabeth Binder; Wolfgang Marg; Esther Bollow; Reinhard Holl Journal: Eur J Pediatr Date: 2015-12-15 Impact factor: 3.183
Authors: Roseanne O Yeung; Mohammad Al Jundi; Sriram Gubbi; Maria E Bompu; Sandra Sirrs; Mark Tarnopolsky; Fady Hannah-Shmouni Journal: J Diabetes Complications Date: 2020-04-13 Impact factor: 2.852